Real life evidence on dual therapy with dolutegravir and lamivudine

被引：0
|
作者：
Iglessias, A. C. C. [1 ]
Madruga, J. V. R. [1 ]
Tancredi, M. V. [1 ]
Ramos, L. R. [1 ]
Moraes, C. A. [1 ]
da Costa, A. F. [1 ]
Mendes, C. V. [1 ]
Kalmar, E. M. N. [1 ]
Nogui, F. L. N. [1 ]
Muller, P. R. [1 ]
Leme, S. T. S. [1 ]
Gouveia, J. P. S. [1 ]
Souza, T. V. G. [1 ]
Sasaki, M. [1 ]
Fonsi, M. [1 ]
Carvalho, D. G. [1 ]
da Silva, D. P. [1 ]
de Medeiros, M. F. F. [1 ]
Rodrigues, C. [1 ]
Nogueira, R. S. [1 ]
机构：
[1] Casa Pesquisa, Ctr Referencia & Treinamento DST AIDS, Sao Paulo, Brazil
来源：
HIV MEDICINE | 2023年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
514
引用
收藏
页码：120 / 120
页数：1
相关论文
共 50 条
  • [1] Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy
    Taiwo, Babafemi O.
    Quinones-Mateu, Miguel E.
    Smith, Kimberly
    Zheng, Lu
    Gulick, Roy
    Nyaku, Amesika N.
    Sax, Paul E.
    Ha, Belinda
    Kumwenda, Johnstone
    Olefsky, Maxine
    Godfrey, Catherine
    Wallis, Carole
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2020, 36 (04) : 254 - 255
  • [2] DUAL ANTIRETROVIRAL THERAPY WITH DOLUTEGRAVIR PLUS LAMIVUDINE: REAL WORLD EXPERIENCE FROM THE NORTH EAST OF ENGLAND
    Procter, Isabella
    Hunter, Ewan
    Dixon, Jill
    Duncan, Christopher
    Evans, Adam
    Payne, Brendan
    Price, Ashley
    Schmid, Matthias
    Schwab, Ulrich
    Taha, Yusri
    Duncan, Sarah
    SEXUALLY TRANSMITTED INFECTIONS, 2022, 98 : A43 - A43
  • [3] Dolutegravir plus lamivudine dual therapy - a new option for initial antiretroviral therapy
    Fida, M.
    Rizzo, S. A.
    Temesgen, Z.
    DRUGS OF TODAY, 2019, 55 (05) : 297 - 304
  • [4] Real-Life Experience on Dolutegravir and Lamivudine as Initial or Switch Therapy in a Silver Population Living with HIV
    Mazzitelli, Maria
    Sasset, Lolita
    Gardin, Samuele
    Leoni, Davide
    Trunfio, Mattia
    Scaglione, Vincenzo
    Mengato, Daniele
    Agostini, Elena
    Vania, Eleonora
    Putaggio, Cristina
    Cattelan, Annamaria
    VIRUSES-BASEL, 2023, 15 (08):
  • [5] Effectiveness, Durability, and Safety of Dolutegravir and Lamivudine Versus Dolutegravir, Lamivudine, and Abacavir in a Real-Life Cohort of HIV-Infected Adults
    Mendoza, Ines
    Lazaro, Alicia
    Torralba, Miguel
    ANNALS OF PHARMACOTHERAPY, 2022, 56 (04) : 412 - 421
  • [6] Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
    Maggiolo, Franco
    Gulminetti, Roberto
    Pagnucco, Layla
    Digaetano, Margherita
    Benatti, Simone
    Valenti, Daniela
    Callegaro, Annapaola
    Ripamonti, Diego
    Mussini, Cristina
    BMC INFECTIOUS DISEASES, 2017, 17
  • [7] Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting
    Rocabert, Alba
    Borjabad, Beatriz
    Berrocal, Leire
    Blanch, Jordi
    Inciarte, Alexy
    Chivite, Ivan
    Gonzalez-Cordon, Ana
    Torres, Berta
    Ambrosioni, Juan
    Martinez-Rebollar, Maria
    Laguno, Montserrat
    De La Mora, Lorena
    Foncillas, Alberto
    Sempere, Abiu
    Rodriguez, Ana
    Solbes, Estela
    Llobet, Roger
    Miro, Jose M.
    Mallolas, Josep
    Blanco, Jose L.
    De Lazzari, Elisa
    Martinez, Esteban
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (12) : 2961 - 2967
  • [8] Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
    Franco Maggiolo
    Roberto Gulminetti
    Layla Pagnucco
    Margherita Digaetano
    Simone Benatti
    Daniela Valenti
    Annapaola Callegaro
    Diego Ripamonti
    Cristina Mussini
    BMC Infectious Diseases, 17
  • [9] Dolutegravir, abacavir and lamivudine as HIV therapy
    Vicente Fernandez-Montero, Jose
    Barreiro, Pablo
    Labarga, Pablo
    De Mendoza, Carmen
    Soriano, Vicente
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (07) : 1051 - 1057
  • [10] Lower incidence of liver steatosis in patients treated with lamivudine plus dolutegravir dual therapy
    Moschese, D.
    Ciccullo, A.
    Taccari, F.
    Emiliozzi, A.
    Baldin, G.
    Dusina, A.
    Farinacci, D.
    Lombardi, F.
    Belmonti, S.
    Borghetti, A.
    Di Giambenedetto, S.
    HIV MEDICINE, 2019, 20 : 126 - 126
12345